PALM BEACH, Fla. – The first day of the National Association of Chain Drug Stores Annual Meeting got off to a fast start at a breakfast on GLP-1s sponsored by retailmediaIQ, publisher of Chain Drug Review and MMR. Building on a webinar devoted to the same topic earlier this year, the session addressed the latest developments in a rapidly evolving category that is poised to impact much of what transpires in the food and pharmacy sectors. Moderated by Parag Shah, co-founder, partner and chief growth officer at Think Blue, the panelists included Jim Kirby, chief commercial officer at Kroger Health, Betty Pio, a partner and strategic advisor to pharma and biotech at Kearney, and Sarah Squires, director of Retail Insights Drug Channel at NielsenIQ.
CDR/MMR breakfast at NACDS Annual looks at the latest developments in GLP-1 category
The session addressed the latest GLP-1 developments in a rapidly evolving category that is poised to impact much of what transpires in the food and pharmacy sectors.
Related
Video Forum: Colleen Lindholz, Kroger, and Aaron Wiese, Hy-Vee
The time is right to reimagine retail health.
NACDS Foundation welcomes new members to its board of directors
Directors from Unilever, Kroger Health, Inmar Intelligence, Haleon, Colgate-Palmolive, and Walmart to support the Foundation’s ongoing focus on research and education.
Jim Whitman honored with NACDS’ highest distinction: Sheldon W. Fantle Lifetime Achievement Award
This tribute was particularly significant as Jim has been instrumental in constantly transforming and sustaining the NACDS Annual Meeting and other NACDS meetings and conferences as premier events that foster industry relationships and drive advancement.
Latest
RFK Jr and Dr. Oz announce press conference on health insurance reform
According to a statement, they will discuss a “breakthrough in health insurance that will improve access to care for millions of Americans. "
Kroger Q1 2025: Pharmacy and digital drive strong results
Pharmacy was a standout growth driver, helping boost gross margin to 23%, up from 22% a year ago
Camber Pharmaceuticals launches Chlorpromazine HCl Injection, USP
Chlorpromazine HCl Injection is indicated for the treatment of schizophrenia, severe behavioral problems in children, and manic-depressive illness.
Xlear sues FTC over marketing rules, citing Supreme Court ruling
The suit invokes the Supreme Court’s 2024 Loper Bright Enterprises v. Raimondo decision as the basis for challenging the FTC’s enforcement powers.